IOVA vs. TWST, RLAY, FATE, NKTR, CBPO, RGEN, PCVX, EXEL, RVMD, and HALO
Should you be buying Iovance Biotherapeutics stock or one of its competitors? The main competitors of Iovance Biotherapeutics include Twist Bioscience (TWST), Relay Therapeutics (RLAY), Fate Therapeutics (FATE), Nektar Therapeutics (NKTR), China Biologic Products (CBPO), Repligen (RGEN), Vaxcyte (PCVX), Exelixis (EXEL), Revolution Medicines (RVMD), and Halozyme Therapeutics (HALO). These companies are all part of the "medical" sector.
Iovance Biotherapeutics (NASDAQ:IOVA) and Twist Bioscience (NASDAQ:TWST) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, community ranking, institutional ownership and valuation.
In the previous week, Twist Bioscience had 2 more articles in the media than Iovance Biotherapeutics. MarketBeat recorded 11 mentions for Twist Bioscience and 9 mentions for Iovance Biotherapeutics. Iovance Biotherapeutics' average media sentiment score of 1.00 beat Twist Bioscience's score of 0.52 indicating that Iovance Biotherapeutics is being referred to more favorably in the media.
Iovance Biotherapeutics presently has a consensus price target of $24.64, indicating a potential upside of 216.66%. Twist Bioscience has a consensus price target of $44.00, indicating a potential downside of 12.80%. Given Iovance Biotherapeutics' higher probable upside, equities analysts clearly believe Iovance Biotherapeutics is more favorable than Twist Bioscience.
Twist Bioscience has a net margin of -69.24% compared to Iovance Biotherapeutics' net margin of -23,615.70%. Twist Bioscience's return on equity of -31.61% beat Iovance Biotherapeutics' return on equity.
Iovance Biotherapeutics received 470 more outperform votes than Twist Bioscience when rated by MarketBeat users. Likewise, 74.57% of users gave Iovance Biotherapeutics an outperform vote while only 56.96% of users gave Twist Bioscience an outperform vote.
Iovance Biotherapeutics has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500. Comparatively, Twist Bioscience has a beta of 1.78, indicating that its stock price is 78% more volatile than the S&P 500.
Twist Bioscience has higher revenue and earnings than Iovance Biotherapeutics. Twist Bioscience is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
77.0% of Iovance Biotherapeutics shares are held by institutional investors. 10.4% of Iovance Biotherapeutics shares are held by insiders. Comparatively, 3.9% of Twist Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Iovance Biotherapeutics beats Twist Bioscience on 10 of the 17 factors compared between the two stocks.
Get Iovance Biotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for IOVA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IOVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Iovance Biotherapeutics Competitors List
Related Companies and Tools
